Insider Buying: Conexeu Sciences (NASDAQ:CNXU) Director Acquires $499,998.00 in Stock

Conexeu Sciences Inc. (NASDAQ:CNXU) Director Lynn Sebastian Purcell acquired 166,666 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were purchased at an average cost of $3.00 per share, with a total value of $499,998.00. Following the completion of the acquisition, the director owned 3,118,514 shares in the company, valued at $9,355,542. This trade represents a 5.65% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Conexeu Sciences Trading Up 11.4%

NASDAQ:CNXU opened at $3.33 on Thursday. Conexeu Sciences Inc. has a 1 year low of $2.95 and a 1 year high of $18.79. The firm has a fifty day moving average price of $5.20.

Conexeu Sciences (NASDAQ:CNXU) last released its earnings results on Monday, September 14th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.19). Research analysts forecast that Conexeu Sciences Inc. will post -0.40 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Zacks Research raised Conexeu Sciences to a “hold” rating in a research report on Monday, June 29th. Weiss Ratings assumed coverage on Conexeu Sciences in a research note on Monday, August 17th. They set a “sell (e-)” rating for the company. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Conexeu Sciences presently has an average rating of “Hold” and a consensus target price of $20.00.

Conexeu Sciences Company Profile

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.